MMX

• It’s going to be a bumper time for space missions in 2024 – especially to the Moon, our nearest neighbour.
• Rather than peering through telescopes to look at the stars, I prefer to see them in a vial in my lab.
• So it was a great delight to see the safe return of Nasa’s Osiris-Rex mission from asteroid (101955) Bennu in September 2023.

CLPS missions

• Nasa’s series of Commercial Lunar Payload Service (CLPS) missions, many of which will launch in 2024, are set to bring a variety of instruments to the Moon.
• The CLPS programme is part of Nasa’s Artemis initiative to continue human exploration of the Moon.
• CLPS-2 is timetabled to launch in early January 2024, and there are four other CLPS missions planned for launch throughout the year.

Trailblazer

Continuing the lunar theme, Nasa’s Trailblazer mission travels to the Moon to understand where any water is situated. Is it locked inside rock as part of the mineral structure, or is it deposited as ice on the rocky surface? Trailblazer is currently scheduled for launch in the first quarter of 2024. However, no precise date has been confirmed. It’s a small mission, part of the Artemis human lunar exploration programme.

Chang'e 6

• This is particularly significant because the spacecraft will collect material from the lunar farside – the South Pole Aitkin Basin.
• This is a region where it is believed there is abundant frozen water.

Hera

In September 2022, Nasa’s Dart mission encountered a system consisting of two asteroids called Didymos and Dimorphos, and crashed into Dimorphos (the junior partner). The impact had a purpose: to see if such a collision could divert the asteroid in its path – a necessary goal if ever Earth were to be the target of a direct hit by an incoming asteroid.

• But what we don’t know (and won’t until Hera arrives in 2026) is how effective the impact was.
• Hera will investigate in detail – and its results will help to define Earth’s planetary defence protocol.

Europa Clipper

• Launching almost at the same time as Hera is a Nasa flagship mission: the Europa Clipper to Jupiter’s icy moon, Europa.
• Excitingly, Europa may host life in the form of a substantial fauna analogous to the animals that live on the deep ocean floor around hydrothermal vents.

• Europa Clipper will fly past Europa between 40 and 50 times, taking detailed images of the surface, monitoring the satellite for icy plumes – and, most importantly, looking to see whether this moon has the conditions suitable to support life.
• The investigation will be complemented by observations from Esa’s Juice mission, which is currently on its way to Jupiter.

MMX

• I will finish it with my anticipation of further delights to come.
• The launch of the Japanese Space Agency’s Martian Moon Exploration (MMX) mission to Phobos is currently scheduled for September 2024, and designed to return material to Earth in 2029.

Monica Grady works for The Open University. She receives funding from The UKRI-Science and Technology Facilities Council. She is a Senior Research Fellow at the Natural History Museum, London and Chancellor of Liverpool Hope University. She tweets (X's?) as @MonicaGrady

• Driver: The rapidly rising global food trade is driving the growth of the cold storage market.
• Cold Chain Equipment Market: The global cold chain equipment market size exceeded USD 14.08 billion in 2022, and it is projected to hit around USD 108.37 billion by 2032, growing at a CAGR of 22.64% from 2023 to 2032.
• Carbon Capture and Storage Market: The global carbon capture and storage market size was evaluated at USD 5.99 billion in 2023 and it is expected to touch around USD 35.70 billion by 2032, poised to grow at a CAGR of 21.94% during the forecast period 2023 to 2032.
• Thermal Energy Storage Market: The global thermal energy storage market size was estimated at USD 21.66 billion in 2022 and is projected to surpass around USD 50.57 billion by the year 2032, growing at a notable CAGR of 8.9% during the forecast period 2023 to 2032.

• Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
  Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the termination by mutual agreement of the license with Dr. Falk Pharma for Rifamycin SV MMX® in the EU and other selective countries.
• Rifamycin SV MMX® is an orally administered, delayed-release, non-systemic antibiotic approved for the treatment of Travelers' Diarrhea caused by certain bacteria.
• It is the first antibiotic engineered with Cosmo’s proprietary Multi Matrix Technology (MMX®).
• MMX technology is designed to deliver the active pharmaceutical ingredients in a delayed and controlled manner directly to the lower intestine.

• Dublin, Ireland – 28 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Ferring Pharmaceuticals (“Ferring”) has received the approval for Cortiment® (budesonide 9 mg MMX tablets) in Japan by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
• First sales of Cortiment® in Japan are expected to begin by end of Q3 2023.
• Cortiment® has been developed by Cosmo and is globally distributed by Ferring, with the exception of the US, where it is distributed by Bausch.
• Alessandro Della Chà, CEO of Cosmo Pharmaceuticals, comments: “We are very pleased with the new success our partner Ferring Pharmaceuticals has achieved with Cortiment®.